One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principall...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusco, Vittorio, Campisi, Giuseppina, Bedogni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935879/
https://www.ncbi.nlm.nih.gov/pubmed/35312858
http://dx.doi.org/10.1007/s00520-022-06982-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935879/
https://www.ncbi.nlm.nih.gov/pubmed/35312858
http://dx.doi.org/10.1007/s00520-022-06982-y

Ejemplares similares